Scarica l'app Stockscreener
1,005.39
1.57%
16.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$988.62
Aprire:
$993.12
Volume 24 ore:
2.65M
Relative Volume:
0.66
Capitalizzazione di mercato:
$951.27B
Reddito:
$59.42B
Utile/perdita netta:
$18.41B
Rapporto P/E:
49.72
EPS:
20.2197
Flusso di cassa netto:
$6.44B
1 W Prestazione:
+8.46%
1M Prestazione:
+20.47%
6M Prestazione:
+32.90%
1 anno Prestazione:
+22.63%
Intervallo 1D:
$990.10
$1,022.42
Intervallo di 1 settimana:
$900.90
$1,022.42
Portata 52W:
$623.78
$1,022.42
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,005.09 | 865.16B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
194.35 | 453.94B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
230.17 | 386.54B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.09 | 244.07B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
91.77 | 215.32B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Citi bumps Eli Lilly stock target, sees over 50% upside potential - Investing.com
Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch - Benzinga
Here are Wednesday's biggest analyst calls: Nvidia, Apple, Broadcom, Eli Lilly, AT&T, Carvana, Cava, Disney & more - CNBC
Eli Lilly (LLY) Exits CVS Health Plan Over Drug Coverage Dispute - GuruFocus
XtalPi Holdings (SEHK:2228) Is Up 6.6% After Eli Lilly Endorses Ailux AI Platform Partnership Has The Bull Case Changed? - simplywall.st
Lilly reportedly ending CVS drug plan for employees after Novo deal for Wegovy - Seeking Alpha
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' - Benzinga
Eli Lilly licenses vision-restoring gene therapy for $475m - BioXconomy
Citigroup Adjusts Price Target on Eli Lilly and Co. to $1,500 From $1,250, Maintains Buy Rating - MarketScreener
This Unstoppable Growth Stock Just Delivered More Good News: Time to Buy? - AOL.com
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Nov 2025) - 24/7 Wall St.
ABL Bio lands $2.6 bn Eli Lilly deal, capping record year for S.Korean biotech exports - KED Global
Eli Lilly Removes CVS from Employee Drug Plan Following Weight-Loss Drug Snub - Meyka
Can Lilly's (LLY) Latest RNAi Deal Hint at a New Edge in Metabolic Therapies? - Yahoo Finance
Eli Lilly Stock Jumps Premarket On Dumping CVS Drug Plan After Wegovy Snub — Retail Calls It A Pushback Against PBM Power - Stocktwits
3 Forces That Could Shake Eli Lilly Stock - Trefis
Eli Lilly is fundamental building block of Irish export economy - The Irish Times
ABL Bio to Transfer ‘Grabody-B’ Platform to Lilly in Deal Worth up to $2.56 Billion - Businesskorea
Eli Lilly drops CVS drug plan for workers after Novo obesity deal, Bloomberg News reports - 1470 & 100.3 WMBD
Lilly Drops CVS Drug Plan for Workers After Novo Deal - Bloomberg.com
Novo Nordisk cuts Wegovy price in India by up to 37% in rivalry with Eli Lilly's Mounjaro | Business News - Hindustan Times
Elon Musk Finds It ‘Cool’ That Eli Lilly CEO Uses Grok As One Of His Daily Advisors - Stocktwits
Eli Lilly Switches to Rightway After CVS Health's Rejection - Devdiscourse
Lilly Drops CVS Drug Plan for Workers After Novo Obesity Deal - Bloomberg.com
Celltrion clears U.S. approval for Eli Lilly plant acquisition - 매일경제
Why cutting drug prices is pushing Eli Lilly’s stock toward an all-time high - MSN
Eli Lilly (LLY) Is Up 7.8% After Expanding Access and Partnerships in Obesity and Metabolic Therapies - simplywall.st
Lilly Beats Ex-Worker’s Suit Over Denial of Severance Benefits - Bloomberg Law News
Why cutting drug prices is pushing Eli Lilly’s stock to all-time highs - MarketWatch
Eli Lilly Stock (LLY) Hits All-Time High as Post-Earnings Rally Accelerates - TipRanks
Jim Cramer on Eli Lilly: “We’re Not a Seller” - Insider Monkey
Lilly stitches 'Queer Eye' star Tan France into Zepbound campaign to unravel obesity stigma - Fierce Pharma
Eli Lilly stock soars to new highs, Novo Nordisk lags. Here's why. - Yahoo Finance
Trifecta Health cooperated with Eli Lilly to provide patients with access to Zepbound single-dose vials - MarketScreener
Eli Lilly’s Landmark Agreement Set to Transform Weight-Loss Medication Landscape - AD HOC NEWS
Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock? - Yahoo Finance
MeiraGTx stock price target raised to $30 by Piper Sandler on Eli Lilly deal - Investing.com Canada
Eli Lilly divulges new GCGR agonists - BioWorld MedTech
Eli Lilly moves closer to $1 trillion market cap - MarketWatch
Eli Lilly’s Strategic Investments Propel Stock Surge: November 11 Analysis - Meyka
Weight-loss treatment: How has obesity medicine market become battleground for pharma giants like Pfizer, - The Economic Times
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market? - The Motley Fool
Celltrion cleared to buy US Eli Lilly plant - The Korea Herald
Lilly moves deeper into RNAi with $1.2B Sanegene obesity deal - BioWorld MedTech
Celltrion completes acquisition of Eli Lilly US plant, plans CMO expansionCHOSUNBIZ - Chosun Biz
Trump administration makes deal with Eli Lilly, Novo Nordisk to lower GLP-1 prices - drugdiscoverytrends.com
Eli Lilly (LLY) Experiences Analyst Downgrade and Price Target I - GuruFocus
Lilly Expands AI Ties to Insilico, from Customer to Drug Discovery Partner - Genetic Engineering and Biotechnology News
Eli Lilly cuts surprising deals with upstart biotech players - TheStreet
Pharma Partnerships Expand as Eli Lilly Announces Strategic Collaborations with MeiraGTx and SanegeneBio - Pharmaceutical Executive
Stock Movers: Nvidia, Eli Lilly, Centene - Bloomberg.com
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):